ERBB2 and cancer: Patients presenting with HER2/neu negative cancer were treated with chemotherapy (cyclophosphamide +/− anthracyclines and taxanes; 19 women; median age 34 (25–42)) and patients presenting with HER2/neu positive cancer were treated with chemotherapy and trastuzumab (14 women; median age 36 (26–42)).